← SEC 公告列表 | LKFT SEC 公告 | Lakefront Biotherapeutics（LKFT）

重大事件 外國發行人報告 6-K 2026-08-04

Lakefront Biotherapeutics回購逾9.7萬股涉資238.6萬歐元

於 SEC 網站開啟原文

AI 繁中摘要

Lakefront Biotherapeutics（前稱Galapagos，Euronext及NASDAQ代號：LKFT）於2026年8月4日發佈6-K文件，公佈股份回購計劃的最新進展。🔬 **回購詳情** 於2026年7月27日至31日期間，Lakefront透過獨立金融中介機構以酌情授權方式，在Euronext布魯塞爾、阿姆斯特丹及另類交易平台等市場合共回購97,497股普通股，總作價約238.6萬歐元，平均每股購入價24.48歐元，最低及最高價分別為23.68歐元及25.04歐元。截至7月31日收市，公司持有自身普通股合共704,216股。 **公司背景** Lakefront為一間生物科技企業，專注於免疫學及炎症領域，核心資產為潛在同類首創（first-in-class）的BCMA×CD3 T細胞銜接器藥物gamgertamig，用於治療自身免疫性疾病。公司表示具備深厚交易能力、營運靈活性及強勁資本狀況，會持續物色並推進具潛在影響力的高質素藥物資產。 **投資者影響** 是次回購屬2026年6月9日公佈的股份回購計劃一部分，反映管理層對公司價值及前景的信心，或對每股盈利及股價有正面支持作用。公司同時提醒，相關前瞻性陳述存在風險與不確定性，投資者應參閱其向SEC提交的20-F年報及後續文件。📊
展開英文正文 
EX-99.1
2
exh_991.htm
PRESS RELEASE

EdgarFiling

EXHIBIT 99.1
Acquisition of Own Shares

 Mechelen, Belgium; 04 August 2026, 22.01 CET; regulated information
 Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 27, 2026 and July 31, 2026, it has repurchased 97,497 Lakefront shares between via a discretionary mandate to an independent financial intermediary, as follows:
 Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
27/07/2026XAMS17,14324.70423,425.2424.4624.84
27/07/2026TQEX5924.681,456.1224.6824.68
27/07/2026CEUX2,22824.7255,085.2924.6824.76
27/07/2026AQEU29624.697,308.7124.6624.72
28/07/2026XAMS15,20124.70375,438.8624.5825.04
28/07/2026TQEX98324.6824,263.8824.6424.78
28/07/2026CEUX4,09724.70101,205.3224.6224.84
29/07/2026XAMS16,04724.75397,180.9024.4025.04
29/07/2026TQEX24624.956,136.8924.9224.96
29/07/2026CEUX2,25324.7655,787.4324.4825.02
29/07/2026AQEU47724.8011,830.3624.5024.94
30/07/2026XAMS16,16324.09389,285.8523.8424.36
30/07/2026TQEX19524.124,704.2424.0424.16
30/07/2026CEUX1,82024.1443,927.1623.9824.30
30/07/2026AQEU91724.2522,236.1524.0424.32
31/07/2026XAMS16,49924.11397,787.5923.6824.40
31/07/2026TQEX81024.3719,736.6224.1624.46
31/07/2026CEUX2,06323.9749,443.3023.8624.24
Total 97,49724.482,386,239.9323.6825.04
 As of market close on 31 July 2026, Lakefront holds 704,216 of its own ordinary shares.
 About Lakefront BiotherapeuticsLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
 For further information, contact Lakefront Biotherapeutics:Investor Relations Sherri Spear+1 412 522 [email protected]
 Forward-looking statementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.